Multiple Analyst Targets Lift (Nasdaq: NRXP) To Our #1 Watchlist Spot (Technicals Lean Oversold)

Picture a treatment room in Florida.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Multiple Analyst Targets Lift (Nasdaq: NRXP) To Our #1 Watchlist Spot (Technicals Lean Oversold) *Click Here To Get Our Alerts Faster Via SMS* October 19th Dear Reader, Picture a treatment room in Florida. A robotic arm, first cleared for neurosurgery, holds a magnetic coil beside a patient's head. Each time the patient shifts, AI-driven software re-aims the coil with submillimeter precision. That scene is close to reality. HOPE Therapeutics, the clinic subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), has begun training staff on Zeta Surgical's robotic TMS system, which received FDA 510(k) clearance in July 2026. HOPE is set to be the first interventional psychiatry network to deploy it. Here's why precision matters. TMS is a noninvasive therapy used mainly for treatment-resistant depression, a condition NRx says affects about one-third of patients with major depressive disorder. Hitting the same brain target, session after session, is central to how well TMS performs. The robot did not arrive alone. Weeks later, DARPA turned an earlier selection into a funded prime contract worth approx. $11.2Mn for SPARC-TMS, a Phase II/III trial pairing single-day robotic TMS with NRx's oral therapy NRX-101. Meanwhile, the ket-a-mine story keeps moving. In mid-October, the FDA asked NRx for only minor labeling changes to its preservative-free ket-a-mine ahead of a November 10th, 2026 GDUFA goal date. And the market under all of this is expanding. Grand View Research estimates the TMS system market at $279.5Mn in 2025, projecting $594.5Mn by 2033 at a 9.7% annual growth rate. North America held 57.2% of 2025 revenue. Inside The Room: What Management Told Analysts The August earnings call offered a rare look at how leadership thinks. Dr. Jonathan Javitt, Chairman and CEO of NRx, was blunt about why some TMS clinics have struggled, suggesting the failures “may have been tied to human technicians.” That comment explains the robotics push in one line. H.C. Wainwright's analyst pressed on SPARC-TMS and whether DARPA would back a separate indication filing. Javitt explained that DARPA focuses on military needs, not approvals, and noted that the FDA application fee alone runs close to $5Mn. He also highlighted real-world evidence drawn from 65,000 Americans, presented at a psychopharmacology meeting, showing IV ket-a-mine performed comparably to or better than intranasal esket-a-mine. When Ascendiant Capital's Ed Wu asked about overseas demand, Javitt said international openings exist for both ket-a-mine and NRX-101. The Pivot: A Therapy Developer Becomes A Care Platform Here's the shift most screens miss. NRx no longer looks like a single-asset developer waiting on the FDA. It now owns the clinics, the robotic workflow and the trial infrastructure that connect its therapies to patients. The build-out moved fast. HOPE became the first commercial site for Zeta's TMS Navigation System and treated its first patients by late June. DARPA selected the SPARC-TMS proposal in July, and the robotic system followed. Every step feeds the same thesis: precise stimulation plus a neuroplastic therapy. About The Company: NRx Pharmaceuticals, Inc. NRx is a clinical-stage biopharmaceutical company developing NMDA-targeted therapies for depression, suicidality, PTSD and chronic pain. According to its Q2 10-Q, the company runs four operating arms: NeuroRx holds the product pipeline: preservative-fr-ee ket-a-mine (KETAFREE) under generic review, NRX-100 with Fast Track designation, and NRX-101 with Breakthrough Therapy Designation for suicidal bipolar depression. HOPE Therapeutics operates six Florida locations offering ket-a-mine infusion, TMS and Spravato, with revenue from commercial plans, Medicare and self-pay patients. NRx Defense Systems is the DARPA prime contractor. GeNeuro, Inc. holds clinical-stage antibody programs, including ALS candidate GNK-301, acquired out of a Swiss liquidation. Today, revenue is clinic revenue: approx. $2.2Mn in the first half of 2026. The next layer would be product sales if the FDA approves KETAFREE or NRX-100. Cash stood at approx. $26.7Mn on June 30th, per second-quarter results, and management told analysts that should support operations for at least a year. Additional Sources: NRXP Website. 7 Potential Catalysts Putting (Nasdaq: NRXP) On Our Radar #1. Robotic TMS Gives HOPE A Precision Edge In Florida. HOPE, the clinic arm of NRXP, is set to be the first interventional psychiatry network to deploy Zeta's FDA-cleared robotic TMS system. #2. The Clock Is Running Toward A November 10th Goal Date. A GDUFA goal date of November 10, 2026 now frames the preservative-fr-ee ket-a-mine review at NRXP. #3. Federal Dollars Now Sit Behind The Defense Strategy. The approx. $11.2Mn DARPA contract funds a study of up to 400 adults that NRXP says could potentially support a future NRX-101 filing. #4. Real-World Evidence From 65,000 Patients Supports NRX-100. Management at NRXP told analysts that real-world data from 65,000 Americans showed IV ket-a-mine performing comparably to or better than intranasal esket-a-mine. #5. A Growing TMS Market Adds A Structural Tailwind. Grand View Research projects the TMS system market to reach $594.5Mn by 2033, a category where NRXP already operates clinics. #6. Analyst Targets Sit Well Above The Recent Close. Benzinga lists 2026 targets on NRXP of $45 from H.C. Wainwright, $50 from Ascendiant Capital and $10 from BTIG. #7. Several Technical Indicators Flash Oversold Leaning Signals. At close on Friday, Barchart was reporting multiple technical indicators to be flashing oversold signals for NRXP including a 9-Day and 14-Day Relative Strength Index both below 31%. Final Word Most companies at NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)’s size ask you to believe in one product. This one is assembling a full care loop: FDA-cleared devices in owned clinics, a ket-a-mine franchise nearing an FDA goal date, and a defense-funded trial tying it together. That is a lot of strategic surface area. With a goal date and an expected earnings report both landing in mid-November, now is the time to consider NRXP for your watchlist and start your homework. Coverage is officially a go on NRx Pharmaceuticals, Inc. (Nasdaq: NRXP). Stay tuned for updates coming your way shortly. Talk soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 10/18/2026 and ending on 10/19/2026 to publicly disseminate information about (NRXP:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). These Funds were part of the forty thousand USD funds that TD Media LLC received from a third party named DMS Consulting LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (NRXP:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/nrxp-teshw/#details

Fierce Investor | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice